生物制剂在克罗恩病治疗中的最佳应用。
Optimal use of biologics in the management of Crohn's disease.
机构信息
Director, Inflammatory Bowel Disease Clinic, Assistant Professor of Medicine, University of Calgary, Rm. 6D32, TRW Building, 3280 Hospital Drive NW, Calgary, Alberta T2N 4N1.
出版信息
Therap Adv Gastroenterol. 2010 May;3(3):179-89. doi: 10.1177/1756283X09357579.
Abstract
Crohn's disease (CD) is a chronic relapsing and remitting disorder of the gastrointestinal tract with no known cure. The inflammation that drives the disease can lead to debilitating symptoms and a number of complications that may lead to surgery. The introduction of biologic therapy a decade ago has offered a new option for patients failing conventional therapy. Over time, biologic therapy has also led to the desire to achieve treatment goals beyond the control of symptoms. In order to achieve short-term and long-term goals with these new agents, it is important to review how these therapies may be optimized for the best results.
摘要
克罗恩病（CD）是一种慢性复发性胃肠道疾病，目前尚无治愈方法。导致疾病的炎症可导致衰弱的症状和许多并发症，可能导致手术。十年前生物治疗的引入为传统治疗失败的患者提供了新的选择。随着时间的推移，生物治疗也促使人们希望实现超越症状控制的治疗目标。为了通过这些新药物实现短期和长期目标，重要的是要回顾如何优化这些治疗以获得最佳效果。
相似文献
1
Optimal use of biologics in the management of Crohn's disease.生物制剂在克罗恩病治疗中的最佳应用。
Therap Adv Gastroenterol. 2010 May;3(3):179-89. doi: 10.1177/1756283X09357579.
2
Comparative Efficacy of Biologic Therapies for Inducing Response and Remission in Fistulizing Crohn's Disease: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.比较生物疗法在诱导瘘管性克罗恩病缓解和应答中的疗效：系统评价和随机对照试验的网络荟萃分析。
Inflamm Bowel Dis. 2023 Mar 1;29(3):367-375. doi: 10.1093/ibd/izac103.
3
Biologics in inflammatory bowel disease: what are the data?炎症性肠病中的生物制剂：有哪些数据？
United European Gastroenterol J. 2015 Oct;3(5):419-28. doi: 10.1177/2050640615590302.
4
Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.两种生物制剂联合治疗难治性克罗恩病的疗效和安全性。
Aliment Pharmacol Ther. 2020 Jun;51(11):1031-1038. doi: 10.1111/apt.15719. Epub 2020 Apr 24.
5
Experience With Anti-TNF-α Biologic Agents in Succession in Patients With Crohn's Disease: A Retrospective Analysis of a Single Center.克罗恩病患者序贯使用抗TNF-α生物制剂的经验：单中心回顾性分析
J Clin Gastroenterol. 2016 Apr;50(4):326-30. doi: 10.1097/MCG.0000000000000338.
6
Treatment Patterns in Newly Diagnosed Patients with Crohn's Disease Who Received Biologics Following Diagnosis: A Nationwide, Retrospective, Longitudinal, Observational Study Using a Medical Claims Database in Japan.在诊断后接受生物制剂治疗的新诊断克罗恩病患者的治疗模式：一项使用日本医疗索赔数据库的全国性、回顾性、纵向、观察性研究。
Digestion. 2023;104(2):109-120. doi: 10.1159/000527045. Epub 2022 Nov 30.
7
Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.英夫利昔单抗和其他抗肿瘤坏死因子 α 治疗药物治疗炎症性肠病。
BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000.
8
Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.比较生物疗法治疗中重度克罗恩病的疗效和安全性：系统评价和网络荟萃分析。
Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1002-1014. doi: 10.1016/S2468-1253(21)00312-5. Epub 2021 Oct 22.
9
Biologic agent use varies inversely with age at diagnosis in Crohn's disease.在克罗恩病中，生物制剂的使用与诊断时的年龄呈反比。
Dig Dis Sci. 2010 Nov;55(11):3164-70. doi: 10.1007/s10620-010-1397-9. Epub 2010 Sep 16.
10
Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.用于维持克罗恩病缓解的肿瘤坏死因子-α抗体。
Cochrane Database Syst Rev. 2008 Jan 23(1):CD006893. doi: 10.1002/14651858.CD006893.
引用本文的文献
1
Paediatric obesity and Crohn's disease: a descriptive review of disease phenotype and clinical course.儿童肥胖与克罗恩病：疾病表型与临床病程的描述性综述
Paediatr Child Health. 2023 Sep 16;29(3):158-162. doi: 10.1093/pch/pxad065. eCollection 2024 Jun.
2
Immunogenicity and Loss of Effectiveness of Biologic Therapy for Inflammatory Bowel Disease Patients Due to Anti-Drug Antibody Development.炎症性肠病患者生物治疗因抗药抗体产生导致的免疫原性及疗效丧失
Antibodies (Basel). 2024 Feb 26;13(1):16. doi: 10.3390/antib13010016.
3
Treatment escalation and de-escalation decisions in Crohn's disease: Delphi consensus recommendations from Japan, 2021.《2021 年日本克罗恩病治疗升级和降级决策：德尔菲共识建议》。
J Gastroenterol. 2023 Apr;58(4):313-345. doi: 10.1007/s00535-023-01958-z. Epub 2023 Feb 11.
4
Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease.炎症性肠病中抗肿瘤坏死因子治疗无应答及应答丧失的管理
Front Med (Lausanne). 2022 Jun 15;9:897936. doi: 10.3389/fmed.2022.897936. eCollection 2022.
5
Diet as therapeutic intervention in Crohn's disease.饮食作为克罗恩病的治疗干预措施。
Prz Gastroenterol. 2022;17(2):96-102. doi: 10.5114/pg.2022.116376. Epub 2022 May 19.
6
Kono-S anastomosis for Crohn's disease: a systemic review, meta-analysis, and meta-regression.克罗恩病的 Kono-S 吻合术：系统评价、荟萃分析和荟萃回归。
Surg Today. 2021 Apr;51(4):493-501. doi: 10.1007/s00595-020-02130-3. Epub 2020 Sep 7.
7
Dose Escalation Assessment Among Targeted Immunomodulators in the Management of Inflammatory Bowel Disease.靶向免疫调节剂治疗炎症性肠病的剂量递增评估。
J Manag Care Spec Pharm. 2020 Jun;26(6):758-765. doi: 10.18553/jmcp.2020.19388. Epub 2020 Mar 19.
8
Immunogenicity of biologics in inflammatory bowel disease.生物制剂在炎症性肠病中的免疫原性。
Therap Adv Gastroenterol. 2018 Jan 21;11:1756283X17750355. doi: 10.1177/1756283X17750355. eCollection 2018.
9
A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease.一项关于比较炎症性肠病的传统、生物和手术干预措施的成本效益研究的系统评价。
PLoS One. 2017 Oct 3;12(10):e0185500. doi: 10.1371/journal.pone.0185500. eCollection 2017.
10
Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States.美国溃疡性结肠炎和克罗恩病患者随时间推移生物治疗欠佳的指标
PLoS One. 2017 Apr 20;12(4):e0175099. doi: 10.1371/journal.pone.0175099. eCollection 2017.
本文引用的文献
1
The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies.在两种其他抗 TNF 抗体治疗失败后，一种新的抗 TNF 单克隆抗体在克罗恩病中的疗效和安全性。
Aliment Pharmacol Ther. 2010 Jan;31(1):92-101. doi: 10.1111/j.1365-2036.2009.04130.x.
2
Sequential therapies for Crohn's disease: optimizing conventional and biologic strategies.克罗恩病的序贯疗法：优化传统和生物治疗策略
Rev Gastroenterol Disord. 2008 Spring;8(2):109-16.
3
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.接受定期英夫利昔单抗维持治疗的克罗恩病患者免疫抑制的撤减：一项随机试验
Gastroenterology. 2008 Jun;134(7):1861-8. doi: 10.1053/j.gastro.2008.03.004. Epub 2008 Mar 8.
4
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.新诊断克罗恩病患者早期联合免疫抑制治疗或传统治疗：一项开放性随机试验
Lancet. 2008 Feb 23;371(9613):660-667. doi: 10.1016/S0140-6736(08)60304-9.
5
Maintenance therapy with certolizumab pegol for Crohn's disease.聚乙二醇化赛妥珠单抗用于克罗恩病的维持治疗。
N Engl J Med. 2007 Jul 19;357(3):239-50. doi: 10.1056/NEJMoa062897.
6
Certolizumab pegol for the treatment of Crohn's disease.聚乙二醇化赛妥珠单抗用于治疗克罗恩病。
N Engl J Med. 2007 Jul 19;357(3):228-38. doi: 10.1056/NEJMoa067594.
7
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.那他珠单抗治疗活动性克罗恩病：ENCORE试验结果
Gastroenterology. 2007 May;132(5):1672-83. doi: 10.1053/j.gastro.2007.03.024. Epub 2007 Mar 21.
8
Infliximab dose intensification in Crohn's disease.英夫利昔单抗在克罗恩病中的剂量强化
Inflamm Bowel Dis. 2007 Sep;13(9):1093-9. doi: 10.1002/ibd.20177.
9
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.阿达木单抗用于曾接受英夫利昔单抗治疗的克罗恩病诱导治疗：一项随机试验。
Ann Intern Med. 2007 Jun 19;146(12):829-38. doi: 10.7326/0003-4819-146-12-200706190-00159. Epub 2007 Apr 30.
10
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.英夫利昔单抗诱导和维持治疗儿童中重度克罗恩病
Gastroenterology. 2007 Mar;132(3):863-73; quiz 1165-6. doi: 10.1053/j.gastro.2006.12.003. Epub 2006 Dec 3.
Zotero 插件